Geoffrey M. Glass Takes the Helm as CEO of Abzena, Promising Continued Growth

Abzena's New Leadership with Geoffrey M. Glass as CEO

Abzena, a trailblazer in the integrated Contract Development and Manufacturing Organization (CDMO) and Contract Research Organization (CRO) scene, has announced the appointment of Geoffrey M. Glass as its new Chief Executive Officer, effective immediately. Previously, Glass served as Chairman of the Board since 2022. His extensive experience and proven track record make him a fitting leader for Abzena as it continues its impressive trajectory in the life sciences industry.

With a career spanning three decades, Glass has cultivated expertise in life sciences and has been instrumental in the evolution of the CDMO sector over the last 15 years. His past executive roles at companies like EY Consulting, Valeant Pharmaceuticals (now Bausch Health), and Patheon (now part of Thermo Fisher Scientific) have equipped him with a well-rounded perspective on both the innovator and service sides of the industry.

In his statement, Glass expressed enthusiasm for his new role, stating, “Over the past few years, Abzena has made incredible progress through operational execution and strengthening our unique scientific capabilities. These efforts have delighted many of our customers and have also led to significant growth.” His commitment to maintaining and amplifying this momentum bodes well for the company's future.

Glass emphasized the importance of collaboration within the organization, looking forward to working closely with the talented team at Abzena to support clients and, more importantly, the patients they serve.

Board of Directors' Endorsement

The Board of Directors expressed confidence in Glass's capabilities as a leader, noting his strategic mindset, operational focus, and strong customer-centric approach. They termed him “the right person to lead Abzena in its next phase,” highlighting the company's solid position for future success. With new leadership at the helm, stakeholders can anticipate a continuation of the company's trajectory in the biopharmaceutical sector.

About Abzena

Abzena has distinguished itself as a leading CDMO and CRO for complex biologics and bioconjugates. The company plays a crucial role in supporting clients from early discovery through to commercial launch by offering integrated programs or individual services that de-risk and streamline the development of new treatments. By tailoring strategies to each project, Abzena enables biotech and biopharma companies to maximize the potential of their molecules and expedite their medicines' progress to market.

Abzena operates research, development, and current Good Manufacturing Practice (cGMP) facilities located in San Diego, California, Bristol, Pennsylvania, and Cambridge, UK. The company is owned by Welsh, Carson, Anderson & Stowe, a globally recognized private equity investment firm. For more information about Abzena and its services, visit abzena.com.

As Abzena embarks on this new chapter under Glass's leadership, stakeholders will be keenly observing how his vision and strategies unfold, particularly in enhancing client and patient outcomes in the evolving landscape of life sciences.